Levi Strauss & Co. vs uniQure N.V. Ordinary Shares — how do they compare? Levi Strauss & Co. trades at $19.56 (market cap $7.47B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: Levi Strauss & Co. is far larger — about 5× uniQure N.V. Ordinary Shares's market cap, and Levi Strauss & Co. pays a 3.29% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Levi Strauss & Co. for 71 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| LEVI | QURE | |
|---|---|---|
Market Cap | $7.47B | $1.48B |
Volume | 6,427,839 | 2,488,780 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $70.59 |
52-Week Low | $17.92 | $9.03 |
Typical Hold Time | 71 Days | 0 Days |
Enterprise Value | $9.02B | $728.62M |
Dividend Yield | 3.29% | — |
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $19.57, up 1.72% with strong fundamentals including a 12.82 P/E ratio and 25.76% ROE. The stock shows bearish technical signals but has consistently beaten earnings expectations for four consecutive quarters. Recent news highlights the company's successful '90s fashion revival and appointment of a new CFO, while analyst consensus remains strongly bullish with a $29 price target representing 48% upside potential.
The investment case balances attractive valuation against technical weakness. Strong profitability metrics and consistent earnings beats support upside, but bearish technical indicators and execution risks in the competitive apparel sector warrant caution. The 78.95% buy rating from analysts suggests significant institutional confidence in Levi's growth trajectory despite near-term market sentiment concerns.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →